Search CCR Clinical Trials

location_on
All trials take place at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland.
airline_seat_individual_suite
Travel and lodging support available for those enrolled on a trial.
person
Trials are available for patients with cancer, HIV, or immunodeficiency disorders.
public
Additional trials taking place at other locations are available on clinicaltrials.gov.

Need help?

Contact one of our clinical trial specialists.

Open - Recruiting

Expanded Use for a Single Patient Using PDS01ADC in Combination with Hepatic Artery Infusion Pump (HAIP) FUDR and Dexamethasone in a Patient with Pancreatic Acinar Cell Carcinoma Metastasized to the Liver
Summary not yet available.

Trial ID
IRB002513

Trial Lead
Jonathan M. Hernandez, M.D.
Open - Recruiting

Phase 1

Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
Learn if you qualify for this trial

Trial ID
IRB001924

Trial Lead
Hoyoung M. Maeng, M.D.

Who to Contact for Questions

Email NCI Medical Oncology Referral Office

Call 888-624-1937
Open - Recruiting

Phase 1

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Learn if you qualify for this trial

Trial ID
IRB002021

Trial Lead
Raffit Hassan, M.D.

Who to Contact for Questions

Email Agra, Maria Gracia

Call +1 240 858 3152
Open - Recruiting

Phase 1

Phase 2

Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
Learn if you qualify for this trial

Trial ID
IRB001811

Trial Lead
Elizabeth M. Hill, M.D.

Who to Contact for Questions

Email NCI Medical Oncology Referral Office

Call 888-624-1937
Open - Recruiting

Screening Protocol for Clinical Trial Eligibility
Summary not yet available.

Trial ID
IRB001863

Who to Contact for Questions

Email NCI Medical Oncology Referral Office

Call 888-624-1937
Open - Recruiting

Phase 3

Confirmatory Study of PRGN-2012 in Patients With RRP
Learn if you qualify for this trial

Trial ID
IRB001969

Trial Lead
Scott M. Norberg, D.O.

Who to Contact for Questions

Email NCI Medical Oncology Referral Office

Call 888-624-1937
Open - Recruiting

MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
Learn if you qualify for this trial

Trial ID
IRB001750

Trial Lead
Ismail Baris Turkbey, M.D.

Who to Contact for Questions

Email NCI Medical Oncology Referral Office

Call 888-624-1937
Open - Recruiting

Phase 2

A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
Learn if you qualify for this trial

Trial ID
IRB001870

Trial Lead
Nicholas D. Klemen, M.D.

Who to Contact for Questions

Email NCI Surgery Branch Immunotherapy Recruitment Center

Call 866-820-4505
Open - Recruiting

Development of Patient-Reported Outcome Measures Assessing Tumor-Related Disfigurement and Appearance Concerns in Neurofibromatosis Type 1
Learn if you qualify for this trial

Trial ID
IRB002268

Trial Lead
Staci Martin Peron, Ph.D.
Open - Recruiting

A Phase 1/2, Open-Label, Basket Study to Assess the Safety, Tolerability, and Anti-Tumor Activity of Afamitresgene Autoleucel in Pediatric Subjects with MAGE-A4 Positive Tumors
Summary not yet available.

Trial ID
IRB001844

Trial Lead
John W. Glod, M.D., Ph.D.

Breadcrumb

Search CCR Clinical Trials

Need help?

Expanded Use for a Single Patient Using PDS01ADC in Combination with Hepatic Artery Infusion Pump (HAIP) FUDR and Dexamethasone in a Patient with Pancreatic Acinar Cell Carcinoma Metastasized to the Liver

Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma

Screening Protocol for Clinical Trial Eligibility

Confirmatory Study of PRGN-2012 in Patients With RRP

MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy

A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

Development of Patient-Reported Outcome Measures Assessing Tumor-Related Disfigurement and Appearance Concerns in Neurofibromatosis Type 1

A Phase 1/2, Open-Label, Basket Study to Assess the Safety, Tolerability, and Anti-Tumor Activity of Afamitresgene Autoleucel in Pediatric Subjects with MAGE-A4 Positive Tumors